Fiscal 2025 Revenue Includes a One-Time Upfront Payment of $3.0 Million in Collaboration Revenue from Zimmer Biomet and $3.2M in Product Revenue. Management to Host ...

Aaron Green, Chief Executive Officer, stated, “We are pleased to have now achieved compliance with both the Nasdaq minimum bid price rule and Nasdaq’s periodic financial reporting rule.” As the ...

New Directors Bring Extensive Leadership Experience in Corporate Strategy and Commercialization. SEATTLE and VANCOUVER, British Columbia, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Achieve ...

LAVA-1266 is a potent bi-specific, T cell engager (bsTCE) that targets CD123+ tumor cells with Vγ9Vδ2-T cells using LAVA’s Gammabody ® platform. The bsTCE was designed to lyse CD123+ tumor cells with ...

Biosphere’s proprietary UV sterilization approach paves the way for a new generation of bioreactors that are simpler, more ...

Cannabix provides updated images of its Breath Collection Unit (“BCU”) and Breath Cartridge technology with several new ...

Immuno-oncological therapies have transformed the cancer treatment landscape. They are however only effective in a subset of patients, requiring the identification of novel immunotherapy targets. The ...

Frontier’s pipeline of precision medicines continues to progress rapidly, with interim clinical data for FMC-376, an ON+OFF KRASG12C inhibitor currently in the Phase 1/2 PROSPER trial, expected 2H ...

To access the live webcast or subsequent archived recording of the company presentation, please visit the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations.

Arjan van Manen joins BioLizard as Commercial Director, bringing over 20 years of commercial leadership experience in life sciences Meet BioLizard’s Arjan van Manen and CEO Liesbeth Ceelen at Biotech ...

MISSOULA, Mont., Jan. 09, 2025 (GLOBE NEWSWIRE) -- FYR, a visionary biotechnology company leveraging extracellular vesicles (EVs) to dynamically observe disease and treatment responses, today ...

ElevateBio is a technology-driven company built to power transformative genetic medicines today and for many decades to come. The Company commercializes its enabling technologies, manufacturing ...